TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00619619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Description: DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
Study: NCT04166669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001
Description: Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001
Description: Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Cohort 1 Days 15-30: itraconazole 200 mg oral solution QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Cohort 2 Days 15-33: rifampin 600 mg oral QD.
Study: NCT01433952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Vitamin B1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Vitamin B1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Vitamin B1

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01458119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat hydrochloride
Description: Oral capsule QOD
Study: NCT01224756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinoridine HCl
Description: Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
Study: NCT02798237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training
Description: Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control (overground walking)
Description: Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
Study: NCT02777853

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
Study: NCT01230866

Intervention type: RADIATION
Group type: OTHER
Intervention: Proton Radiation Hypofractionation
Description: Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Radiation Standard Fractionation
Description: Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
Study: NCT00503854

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Ancillary studies
Study: NCT03364985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets
Study: NCT00659633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
Study: NCT03364985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®
Study: NCT05990205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life Style Intervention + Metformin
Description: hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Style Intervention
Description: hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week)
Study: NCT03884595

Intervention type: DIAGNOSTIC_TEST
Intervention: IG, IPF, NRBC, CRP, PCT, presepsin
Description: Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: IG, IPF, NRBC, CRP, PCT, presepsin
Description: Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: IG, IPF, NRBC, CRP, PCT, presepsin
Description: Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: IG, IPF, NRBC, CRP, PCT, presepsin
Description: Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.

Intervention type: DIAGNOSTIC_TEST
Intervention: IG, IPF, NRBC, CRP, PCT, presepsin
Description: Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.
Study: NCT03218410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical pulmonary embolectomy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: catheter-directed thrombolysis
Study: NCT01866488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02175654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study: NCT00543582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103 and Azacitidine
Description: In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops.
Study: NCT02372682

Intervention type: DEVICE
Intervention: Shear wave sonoelastography
Description: Sonoelastography is to be performed on the liver.

Intervention type: DEVICE
Intervention: Shear wave sonoelastography
Description: Sonoelastography is to be performed on the liver.
Study: NCT02482571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mild Hypoxia
Description: During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from \~21% (room air) to \~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
Study: NCT01726335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone prolonged release
Description: Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
Study: NCT01420835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy (protocol group)
Description: The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without protocol group
Description: The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
Study: NCT03861390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
Study: NCT00964574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE (HMR1964)
Description: Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening
Study: NCT01667718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth 220mg b.i.d for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg b.i.d.for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg b.i.d.for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoﬂoxacin
Description: Levoﬂoxacin 0.5 q.d. for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoﬂoxacin
Description: Levoﬂoxacin 0.5 q.d. for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1 g b.i.d. for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 1 g b.i.d. for 2 weeks
Study: NCT01325363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetoencephalograph (MEG)
Description: Brain imaging device that records the magnetic fields in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetoencephalograph (MEG)
Description: Brain imaging device that records the magnetic fields in the brain.
Study: NCT04161469

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser closure of the anal fistula tract (FiLaC)
Description: The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser closure of the anal fistula tract (FiLaC)
Description: The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal orifice closure
Description: Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
Study: NCT01159041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Treatment (FFT)
Description: FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.
Study: NCT03358667

Intervention type: PROCEDURE
Intervention: augmentation peri-implant soft tissue
Description: the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
Study: NCT01159041

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Treatment (IP)
Description: The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.
Study: NCT04410107

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function tests
Description: Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function tests
Description: Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise capacity
Description: 6-minute walk test (6MWT distance)

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise capacity
Description: 6-minute walk test (6MWT distance)

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise physiology
Description: Cardiopulmonary exercise test (CPET)
Study: NCT01638793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcap (Oridion, Needham, MA, USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)
Study: NCT00492388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMI-150 (intranasal ketamine)
Description: intranasal dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05037682

Intervention type: OTHER
Group type: OTHER
Intervention: Dissemination and Implementation Research
Description: The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
Study: NCT03213054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: OBP-301 administration on the Day 1, Day 18 and Day 32

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
Study: NCT03899974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test meal
Description: Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch.